Brief: Kezar Life Sciences Reports Q4 And Year End 2022 Financial Results And Provides Business Update

Kezar Life Sciences

14/03/2023 21:35

March 14 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES REPORTS FOURTH QUARTER AND YEAR END
2022
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED
$276.6
MILLION AS OF DECEMBER 31, 2022
    * PALIZADE PHASE 2B CLINICAL TRIAL EVALUATING ZETOMIPZOMIB
IN
LUPUS NEPHRITIS TO INITIATE IN FIRST HALF OF 2023
    * KZR-261 DOSE ESCALATION STUDY CURRENTLY ENROLLING SIXTH
COHORT;
DOSE EXPANSION STUDY EXPECTED TO INITIATE IN H2 OF 2023
    * NET LOSS FOR THE FOURTH QUARTER OF 2022 WAS $18.2 MILLION,
OR
$0.25 PER BASIC AND DILUTED COMMON SHARE
    * Q4 EARNINGS PER SHARE VIEW $-0.28 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw17fQCra 
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))